Zevra Therapeutics Third Quarter 2026 Results - ZEVRA THERAPEUTICS INC

Financial Performance:

• Total net revenue reached $37.8 million in Q3 2026, representing a 45% year-over-year increase from $26.1 million in Q3 2025.
• U.S. net product revenue from MyPlypha (Aramoclomol) was $34 million, growing 52% year-over-year and 12.6% sequentially.
• Revenue composition included $3.6 million from Global Expanded Access Program (EAP) reimbursements and $0.2 million from OPRUVA.
• Net income turned positive at $19.2 million ($0.31 basic, $0.26 diluted per share) compared to a net loss of $0.5 million in the prior year period.
• A non-cash fair value credit of $5.5 million related to outstanding common stock warrants contributed to the net income.
• Operating expenses were $24.1 million, with R&D at $4.9 million (up 30% YoY) and SG&A at $19.1 million (up 13% YoY).
• Cash, cash equivalents, and investments stood at $270.9 million as of Q3 2026, providing sufficient liquidity to advance strategic priorities.

Guidance and Future Outlook:

• Management anticipates filing a Supplemental New Drug Application (SNDA) to expand MyPlypha's label to include infants under 24 months in Q1 2027.
• The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) opinion is expected in Q4 2026 following the re-examination process.
• A decision from the U.S. Patent and Trademark Office (USPTO) regarding patent term extension is anticipated in 2027.
• For the Solipilol Phase III DISCOVER trial (VEDS), management plans to develop a statistical analysis plan including real-world data sets to potentially accelerate the program, with a follow-up FDA discussion targeted for the first half of 2027.
• No full 2027 guidance was provided, but management expects SG&A to remain disciplined without major increases in marketing spend.

Business Segments and Product Lines:

• MyPlypha (Aramoclomol) is the primary revenue driver, with 197 cumulative prescription enrollments since U.S. launch, including 13 in Q3 2026.
• The patient population mix is roughly 50% pediatric and 50% adult, with 123% quarter-over-quarter growth in disease awareness website traffic (25,000 to 56,000 visits).
• The Global EAP has enrolled 134 patients and expanded to an additional territory to improve access.
• Solipilol (Phase III) for Vascular Ehlers-Danlos Syndrome (VEDS) has enrolled 72 patients total (6 new in Q3), with 4 confirmed events against an interim analysis trigger of 28.
• Zebra (Zevra) is expanding its customer-facing sales team to reach newly diagnosed patients in community practices outside Centers of Excellence.

Market and Competitive Landscape:

• Management estimates the U.S. NPC prevalence to be between 300-350 diagnosed patients (current estimates) and potentially up to 900, citing rising diagnosis rates and updated claims data analysis.
• The market is expanding; Shinogi's acquisition of Intrabio to develop a competing NPC therapy is viewed as validating the market opportunity and driving collective disease awareness.
• MyPlypha holds a strong competitive position as the only approved therapy with established data for use in combination with Miglustat, supported by consensus clinical guidelines.
• Payer coverage for MyPlypha stands at 69%, with the remainder largely accessed via medical exception pathways.

Risks and Challenges:

• Diagnostic latency remains a challenge, as NPC symptoms are variable and often misdiagnosed (e.g., initially misdiagnosed as multiple sclerosis in some adult patients).
• Regulatory risk exists regarding the EMA re-examination of Aramoclomol in Europe and the timeline for the USPTO patent term extension decision.
• The pipeline faces development risks, particularly regarding the data requirements and FDA strategy for accelerating the Solipilol VEDS trial.
• Market share depends on continued execution of patient identification and awareness strategies in a small, specialized population.

Management Commentary and Tone:

• The tone was highly confident and optimistic, emphasizing disciplined execution, strong financial footing, and the "life-changing" nature of their therapies.
• Management expressed strong conviction that the total addressable market for NPC is larger than the 2021 estimates, driven by increased awareness and earlier diagnosis.
• The strategy focuses on a "foundation" approach: identifying patients, accelerating diagnosis, and expanding access.
• Leaders highlighted the company's ability to pivot and scale sales operations quickly based on new data.

Analyst Questions and Answers:

• Market Size: Analysts asked if the market is saturated; management clarified that the 350-900 estimate range is being validated upward, and the 50/50 adult/pediatric split in enrollments supports a larger total population.
• Label Expansion: Clarification was provided that the SNDA for infants <24 months adds approximately 5% to the total patient count but is strategically important for label breadth and access.
• Competition: Analysts queried the impact of Shinogi/Intrabio; management stated this validates the market and reinforces MyPlypha's position as the only combination therapy approved.
• Reimbursement: On the trend of net realized price per patient, management reported stable, strong reimbursement rates and high refill rates, driven by clinical data and payer engagement.
• Sales Strategy: Regarding the need for a larger field team, management indicated the current modest expansion is sufficient, with a flexible model to scale up or down as market insights evolve.
• Pipeline: No specific new indications or formulations for MyPlypha were detailed beyond the label expansion, though the IP portfolio extends to 2041.

Other Key Points:

• Intellectual property protection includes Orange Book listed patents expiring in 2041 and U.S. orphan drug exclusivity through 2031.
• Real-world evidence published in Q3 confirms sustained disease stabilization across age groups, supporting long-term efficacy.
• The company utilizes a proprietary analytics model to identify healthcare professionals treating NPC patients.
• The "Expert Connect" program provides direct access for clinicians to NPC specialists to aid in treatment decision-making.